Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis. - Full Text View

Purpose

The aim of this study is to determine the safety and efficacy of daptomycin when used as an adjuvant agent to standard care in the treatment of proven native valve Enterococcal endocarditis. Patients with this disease will be offered the option of receiving daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving. The hypothesis of this study is that daptomycin added to standard therapy for Enterococcal endocarditis is safe and efficacious.

Patients who receive daptomycin + standard therapy will be compared to patients who receive standard therapy alone with respect to the following outcomes:

Safety.
1. The frequency of any Grade 3 or 4 toxicity (DAIDS scale) will be measured.
2. The frequency of muscle toxicity or renal toxicity, as determined by predefined criteria.
Efficacy.
1. Clinical efficacy.
  - Time to clearance of bacteremia
  - Cure at 6 weeks following completion of antibiotic therapy
  - Mortality at 6 weeks following completion of antibiotic therapy
2. Microbiologic efficacy.
  - Peak and trough serum bactericidal titers
  - The minimum bactericidal concentration of Enterococci to daptomycin

We expect to enroll 40 patients over 2 years.

Condition	Intervention	Phase
Endocarditis, Bacterial	Drug: Daptomycin	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: No masking Primary Purpose: Treatment
Official Title:	Open Label Study to Assess the Efficacy and Safety of Daptomycin in Combination With Anti-Cell Wall Active Therapy in the Treatment of Enterococcal Endocarditis

Resource links provided by NLM:

MedlinePlus related topics: Endocarditis

Drug Information available for: Daptomycin

U.S. FDA Resources

Further study details as provided by Rhee, Kyu Y., Weill Medical College of Cornell University:

Primary Outcome Measures:

Number of Participants With Any Grade 3 or 4 Toxicity (DAIDS Scale) [ Time Frame: weekly ]
Number of Participants any Grade 3 or 4 toxicity (DAIDS scale); please see adverse event table for details
Number of Participants With Muscle Toxicity or Renal Toxicity, as Determined by Predefined Criteria [ Time Frame: weekly ]
Number of Participants with creatine kinase elevation > 3x upper limit of normal or elevations of serum Cr >= 30% above baseline


Enrollment:	6
Study Start Date:	September 2006
Study Completion Date:	October 2008
Primary Completion Date:	October 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Daptomycin adjunctive group Patients with enterococcal endocarditis who elect to receive daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving	Drug: Daptomycin daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis Other Name: Cubicin
No Intervention: standard of care Patients with enterococcal endocarditis who elect to receive standard of care therapy as prescribed by their primary physician

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age 18 or over
Definite Enterococcal endocarditis, as defined by modified Duke criteria
Able to complete follow-up 3 and 6 weeks following completion of intravenous antibiotic therapy

Exclusion Criteria:

Pregnancy or breast feeding
Creatine phosphokinase levels over two times the upper limit of normal
Renal insufficiency or dialysis requirement.
Presence of chronic indwelling bloodstream catheters or foreign body devices suspected as primary or secondary sites of enterococcal infection unamenable to removal or replacement
Inability to discontinue or abstain from use of a HMG CoA reductase inhibitor during the study period.
Hypersensitivity to any of the study medications.
Any condition that, in the investigator's opinion, may interfere with protocol compliance including, but not limited to, active substance abuse and/or dementia.
Prosthetic valve endocarditis

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00401960

Locations


United States, New York
NewYork-Presbyterian Hospital, Weill Cornell Campus
New York, New York, United States, 10021

Sponsors and Collaborators

Weill Medical College of Cornell University

Investigators


Principal Investigator:	Kyu Y Rhee, MD, PhD	Weill Medical College of Cornell University

More Information


Responsible Party:	Rhee, Kyu Y., Assistant Professor, Weill Medical College of Cornell University
ClinicalTrials.gov Identifier:	NCT00401960 History of Changes
Other Study ID Numbers:	0507008023
Study First Received:	November 20, 2006
Results First Received:	December 29, 2016
Last Updated:	April 6, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No
Plan Description:	This was a pilot single arm study, for which IPD are not pertinent

Keywords provided by Rhee, Kyu Y., Weill Medical College of Cornell University:


Enterococcus Daptomycin Endocarditis

Additional relevant MeSH terms:


Endocarditis Endocarditis, Bacterial Heart Diseases Cardiovascular Diseases Bacterial Infections	Cardiovascular Infections Infection Daptomycin Anti-Bacterial Agents Anti-Infective Agents

ClinicalTrials.gov processed this record on July 25, 2017